Safety of sodium-glucose cotransporter 2 inhibitors in kidney transplant recipients with diabetes mellitus
Main finding · Composite renal outcomeResult — go to the resultHazard ratio 0.99 95 % CI 0.65–1.52Authors' conclusion
In KTRs with diabetes, SGLT2i therapy improved glycemic control without increased safety concerns compared to standard treatments. Both groups exhibited similar risks of significant kidney-related events and all-cause mortality. These findings provide crucial insights into the existing limited data concerning this vulnerable population, which faces elevated risks of renal complications and medication-related adverse effects. Ongoing randomized controlled trials will provide additional safety data for SGLT2i in KTRs.
Study context
- Population
- Kidney transplant recipients with DM at a tertiary center; SGLT2i users median age 63, 20 % femalematched cohort
- Exposure
- SGLT2i vs standard diabetes therapy
- SGLT2in = 240
- Outcome
- Renal composite of:
- Dialysis
- Re-transplantation
- Acute kidney failure
- Acute rejection
- Follow-up
- Three years
Methodological detailsmatched, single tertiary centre
- Matched
- Single tertiary centre
Main finding
Composite renal outcome
Hazard ratio
0.99
95 % CI 0.65–1.52
P = 0.970
By group
SGLT2i
8.9 events per 100 patient-years
Non-users
13.3 events per 100 patient-years
As reported in the abstract
Observational data: associations, not effects.
Secondary outcomes
- Glycemic control improved more significantly in SGLT2i users
Safety
UTI, diabetic ulcers, fractures, amputations, DKA, all-cause mortality
- Other outcomes showed comparable or lower risks in SGLT2i users
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →